Introduction
Histidine is an essential amino-acid for both chronically uraemic patients and healthy people. 13 Diets deficient in histidine are associated with development of anaemia in normal people and progression of anaemia in patients with chronic renal failure. When histidine is added to such diets haemoglobin production rises and the anaemia improves.2 Plasma histidine levels are decreased in uraemic patients, and possibly histidine deficiency may contribute to the anaemia of uraemia. 9 Giordano et al. have reported that haematocrit values increased in chronically uraemic patients given oral supplements of dietary histidine.5 6 Anaemia is a serious complication of uraemia and contributes to the morbidity and debility of patients with renal failure. We therefore conducted a double-blind controlled study to evaluate the effects of supplementary histidine on the anaemia of patients with uraemia.
Patients
Only patients who were clinically stable and had not been in hospital, undergone surgical procedures, or lost significant amounts of blood during the preceeding two months were accepted into the study. Selection was limited to patients who were willing to adhere to the experimental protocol and had previously complied with medical therapy. Thus 23 chronically uraemic patients and 43 patients undergoing maintenance dialysis entered the study. Twenty-four patients failed to complete the study because of superimposed illness, kidney transplantation, noncompliance, or death, and their data were not analysed. All patients gave their informed consent. Medicine (Delatestryl) for at least four months before the baseline period and continued to receive it during the study.
All chronically uraemic patients had been azotaemic (creatinine clearance <30 ml/min) for more than one year and 12 patients had been azotaemic for more than two years. During the treatment period serum urea nitrogen values were greater in the histidine group than in the placebo group (P<0-01).
Methods
The patients were observed for six to eight weeks to ensure that they were clinically stable and to obtain baseline data. They were then assigned, with the use of a table of random numbers, to placebo or treatment groups which received either methylcellulose 2 g/day or L-histidine as the free base 4 g/day in identical looking capsules. Both the placebo and histidine were taken in two capsules four times daily-with meals and at bedtime. Eight uraemic patients received histidine and eight received placebo, while 12 dialysis patients were given histidine and 14 placebo.
Six months after the start of the study, baseline data were assessed by an independent observer who did not know the patient. Subsequent entrants into the study were assigned by this observer to either the histidine or placebo group so as to make the initial clinical characteristics of the two groups similar. Neither the patients nor their doctors knew which treatment they were receiving or the results of the study. At the end of treatment selection of data for analysis was performed by a doctor who did not know which group the patient was in. The data were then statistically analysed by independent observers who had no contact with the patients. Data collected during periods of intercurrent illness or blood loss and subsequent convalescence were not analysed.
Compliance with the experimental regimen was assessed by careful questioning, observation of patients, and evaluation of the frequency with which subjects requested repeat prescriptions. Patients who took fewer than four capsules per day were excluded from analysis.
Diet.-The chronically uraemic patients were prescribed at least 40 g/day of primarily high quality protein; the patients undergoing dialysis were generally prescribed 1 g kg-' day-1 of primarily high biological value protein; and diets provided at least 015 MJ kg-, day-' (35 kcal kg-1 day-'). Dietary intake of protein and histidine during the study were estimated by dietary interview techniques with the use of food composition tables.8 ' Patients received daily supplements of multivitamins including folic acid 1 mg/day. Most chronically uraemic patients took a daily supplement of iron during the study or were given iron dextran (Imferon) intramuscularly at the start of the baseline assessment. Subjects und rgoing dialysis received iron dextran intravenously when serum iron levels dropped below 600 ptg/l. No patient received blood transfusions during the study. The reticulocyte count decreased in the chronically uraemic patients on placebo, but in both the chronically uraemic patients and those on dialysis there was no difference in the reticulocyte count between the histidine and the placebo groups. The response of haemoglobin to supplementary histidine was not related to the severity of the anaemia, the plasma histidine level at the start of treatment, or the presence or absence of testosterone therapy.
Serum iron levels did not change during treatment in the chronically uraemic patients. In patients on dialysis serum iron increased only in the group on histidine, but the serum iron levels in these patients were affected primarily by losses during dialysis and the administration of iron dextran. The mean serum vitamin B12 concentrations (± S.D.) of patients on dialysis were 748 + 231 ng/l on histidine and 804 ± 211 ng/l on placebo; no patient had subnormal levels. The white cell count rose slightly only in patients on dialysis receiving placebo (P <005) but remained within normal limits and did not differ from levels in the group receiving histidine. The platelet counts did not change during treatment in any group.
Plasma histidine decreased significantly in the chronically uraemic patients receiving placebo (P<0-02) but not in those receiving histi- 18-8 ± 7-1 8-7 ± 1-9 9-2 ± 1-7 26-4 ± 5-7 27-8 ± 5-1 1-3 ± 0-6 1-2 ± 0-6 19-9 ± 5-7 19-9 ± 
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Conversion: SI to Traditional Units-Serum Iron: 1 ,umol/l 5-6 ,ug/100 ml. Histidine v. placebo for either chronically uraemic patients or patients on dialysis, P = not significant for each column.
dine. In the patients on dialysis plasma histidine rose only in those receiving histidine (P <0 001). During the treatment period the mean daily protein intakes (± S.D.) of the chronically uraemic patients on histidine and placebo were about 64 + 24 g and 66 i 19 g respectively. In the patients on dialysis the daily protein intake was about 75 ± 20 g and 75 ± 16 g for the histidine and placebo groups respectively. The chronically uraemic patients were estimated to have ingested a mean of 1500 mg/day of histidine in their food and those on dialysis 1700 mg/day.
At the end of treatment four patients on dialysis whose haemoglobin levels had remained low (cases 24, 26, 32, and 35) were given Lhistidine 4 g/day for a mean of 14 additional weeks (range [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] weeks). When the code was broken we learnt that two of these patients had already been receiving histidine. The haemoglobin and P.C.V. did not change in any patient, though in the two who had previously received placebo (cases 24 and 26) the plasma histidine increased from a mean 71 icmol/l to 103 jsmol/l.
Discussion
Our results indicate that dietary supplementation with Lhistidine does not increase the haemoglobin or P.C.V. in chronically uraemic patients or those on dialysis. In the latter these values increased significantly only in those receiving placebo, while patients taking histidine experienced a rise of similar magnitude which was not significant. Moreover, improvement in anaemia was very slight in both groups. Jontofsohn et al. 10 recently presented evidence that histidine does not improve the anaemia of uraemia.
The increase in haemoglobin in the dialysis patients may have been related to the fact that data collected during superimposed illness or substantial blood loss were excluded from analysis, but the alternative to excluding such data would have been to increase greatly the variance of such data. Consequently, the response to supplementary histidine would have to have been evaluated in many more patients. In patients on dialysis the quantity of blood lost from sampling (about 25 ml/week), retention in the dialyser (6 ml), and clotted or leaking dialysers (combined incidence about 6%) was similar in both groups. Hence the degree of blood loss in the placebo and histidine groups probably could not have affected our results.
The rise in plasma histidine in the patients on dialysis receiving supplementary histidine confirms our observations on the direct correlation between the plasma level and dietary intake of this amino-acid."1 The failure to observe a rise in plasma histidine in the chronically uraemic patients who were treated with histidine might have reflected decreased histidine intake from food taken during treatment. Renal function decreased during the treatment period in these patients, and their protein intake was reduced. The finding that plasma histidine levels decreased in the chronically uraemic patients receiving placebo supports this possibility.
Histidine is an amino-acid of particular importance for erythropoiesis. There is abundant evidence that diets deficient in histidine are associated with decreased erythropoiesis, though how histidine promotes erythropoiesis is unknown.2 312 It may be pertinent that histidine is an amino-acid which is particularly abundant in the haemoglobin molecule and provides the linkage for iron in the haem moiety to globin. It is not clear why the anaemia did not improve in the patients receiving histidine. Their plasma histidine levels during the baseline period were at least as great as those of normal people ingesting 40-60 g protein diets, 1 and they may have had adequate body histidine pools. Hence the administration of histidine in quantities sufficient to prevent a deficiency possibly promotes erythropoiesis, but additional histidine does not further enhance red-cell production. The relation between histidine and erythropoiesis may thus be similar to that between iron or folic acid and red-cell production.
The amount of dietary histidine necessary for a maximum effect on erythropoiesis is unknown. Our patients took about 1500-1700 mg/day of histidine in their food. The Jones and Howells8 reported the first two cases of group B meningitis in Britain, but though official notifications have warranted epidemiological comment" 10 the group B streptococcus appears to be a much underrated pathogen for man. In 1974, when we were confronted with an apparently explosive increase in group-B-related diseases, we attempted to determine retrospectively the obstetric and perinatal morbidity based on
